For second‐line testing in patients with IgA deficiency, 80% of hospitals applied at least one and 31% used two of three recommended IgG‐based tests (TGA‐IgG, DPG‐IgG, EMA‐IgG), with 6% of hospitals still using AGA‐IgG testing, which is no longer considered valuable for CeD diagnosis (Table 1). The gene discussed is AGA; the disease is selective IgA deficiency disease.